Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, LENZ Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -151.10%, while the net margin is -133.60%. These profitability ratios, combined with a Return on Equity (ROE) of -28.78%, provide a clear picture of how effectively LENZ converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, LENZ competes directly with industry leaders such as IMMX and EBS. With a market capitalization of $428.05M, it holds a significant position in the sector. When comparing efficiency, LENZ's gross margin of 100.00% stands against IMMX's N/A and EBS's 42.70%. Such benchmarking helps identify whether LENZ Therapeutics Inc is trading at a premium or discount relative to its financial performance.
